Draft Clinical Guidelines for the Diagnosis and Treatment of Metabolically Associated Fatty Liver Disease in Children (Non-Alcoholic Fatty Liver Disease)

The authors present modern epidemiological data and features of the etiopathogenesis of metabolically associated fatty liver disease in children (non-alcoholic fatty liver disease), and provide clinical characteristics of various variants of this nosology. Information is provided on laboratory, instrumental and morphological signs of metabolically associated fatty liver disease in children, as well as on methods of prevention, treatment and rehabilitation in accordance with developed clinical guidelines.

1. Vos MV, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319–334. doi: https://doi.org/10.1097/MPG.0000000000001482

2. Ten Hove M, Pater L, Storm G, et al. The hepatic lipidome: From basic science to clinical translation. Adv Drug Deliv Rev. 2020; 159:180–197. doi: https://doi.org/10.1016/j.addr.2020.06.027

3. Abdelmalek MF. Nonalcoholic fatty liver disease: another leap forward. Nat Rev Gastroenterol Hepatol. 2021;18(2):85–86. doi: https://doi.org/10.1038/s41575-020-00406-0

4. Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020;158(7):1851–1864. doi: https://doi.org/10.1053/j.gastro.2020.01.052

5. Crane H, Gofton C, Sharma A, George J. MAFLD: an optimal framework for understanding liver cancer phenotypes. J Gastroenterol. 2023;58(10):947–964. doi: https://doi.org/10.1007/s00535-02302021-7

6. Gofton C, Upendran Y, Zheng MH, George J. MAFLD: How is it different from NAFLD? Clin Mol Hepatol. 2023;29(Suppl):S17–S31. doi: https://doi.org/10.3350/cmh.2022.0367

7. Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019 Jan;76(1):99–128. doi: https://doi.org/10.1007/s00018-018-2947-0

8. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–654.e1–e9; quiz e39–40. doi: https://doi.org/10.1016/j.cgh.2014.04.014

9. Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6(10):864– 873. doi: https://doi.org/10.1016/S2468-1253(21)00183-7

10. Colucci A, Chaira Rocco M, De Anseris A, et al. Pediatric vs. adult NAFLD to MAFLD transition: a welcome but tangled path. Explor Med. 2021;2(4):333–342.

11. Le Garf S, Nègre V, Anty R, Gual P. Metabolic fatty liver disease in children: a growing public health problem. Biomedicines. 2021;9(12):1915. doi: https://doi.org/10.3390/biomedicines9121915

12. Hegarty R, Kyrana E, Fitzpatrick E, Dhawan A. Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges. Ther Adv Endocrinol Metab. 2023;14:20420188231160388. doi: https://doi.org/10.1177/20420188231160388

13. Zhang L, El-Shabrawi M, Baur LA, et al. An international multidisciplinary consensus on pediatric metabolic dysfunctionassociated fatty liver disease. Med. 2024;7(5):797–815. doi: https://doi.org/10.1016/j.medj.2024.03.017

14. Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78:181–205. doi: https://doi.org/10.1146/annurev-physiol-021115-105331

15. Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313–3327. doi: https://doi.org/10.1007/s00018-018-2860-6

16. Antonella M, Pietrobattista A, Maggiore G. Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics? Pediatr Rep. 2024;16(2):288–299. doi: https://doi.org/10.3390/pediatric16020025

17. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388– 1402. doi: https://doi.org/10.1016/j.jhep.2015.11.004

18. Eslam M, Sanyal AJ, George J, et al. International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999– 2014.e1. doi: https://doi.org/10.1053/j.gastro.2019.11.312

19. Vittorio J, Lavine JE. Recent advances in understanding and managing pediatric nonalcoholic fatty liver disease. F1000Res. 2020;9:F1000 Faculty Rev-377. doi: https://doi.org/10.12688/f1000research.24198.1

20. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118(4):1388– 1393. doi: https://doi.org/10.1542/peds.2006-1212

21. Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(1 Suppl):S47–S64. doi: https://doi.org/10.1016/j.jhep.2014.12.012

22. Zhao Y, Wang SZ, Zhao YB, et al. Mitochondrial dysfunction in metabolic dysfunction fatty liver disease (MAFLD). Int J Mol Sci. 2023;24(24):17514. doi: https://doi.org/10.3390/ijms242417514

23. Branković M, Dukić M, Gmizić T, et al. New Therapeutic approaches for the treatment of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and increased cardiovascular risk. Diagnostics (Basel). 2024;14(2):229. doi: https://doi.org/10.3390/diagnostics14020229

24. Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005;115(3):e290–e296. doi: https://doi.org/10.1542/peds.2004-1808

25. DeVore S, Kohli R, Lake K, et al. A multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD. J Pediatr Gastroenterol Nutr. 2013;57(1):119–123. doi: https://doi.org/10.1097/MPG.0b013e318290d138

26. Alfani R, Vassallo E, De Anseris AG, et al. Pediatric fatty liver and obesity: not always just a matter of non-alcoholic fatty liver disease. Children (Basel). 2018;5(12):169. doi: https://doi.org/10.3390/children5120169

27. Vimalesvaran S, Vajro P, Dhawan A. Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives. Hepatol Int. 2024;18(Suppl 2):873–883. doi: https://doi.org/10.1007/s12072-024-10691-5

28. Peterkova VA, Nagaeva EV, Shiryaeva TYu. Otsenka fizicheskogo razvitiya detei i podrostkov: Methodological recommendations. Moscow; 2017. 98 p. (In Russ).

29. Maevskaya MV, Kotovskaya YuV, Ivashkin VT, et al. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii Arkhiv. 2022;94(2):216–253. (In Russ). doi: https://doi.org/10.26442/00403660.2022.02.201363

30. Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. doi: https://doi.org/10.1155/2012/145754

31. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986. https://doi.org/10.1097/HEP.0000000000000520

32. Draijer LG, Feddouli S, Bohte AE, et al. Comparison of diagnostic accuracy of screening tests ALT and ultrasound for pediatric nonalcoholic fatty liver disease. Eur J Pediatr. 2019;178(6):863–870. doi: https://doi.org/10.1007/s00431-019-03362-3

33. Draijer L, Benninga M, Koot B. Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. Expert Rev Gastroenterol Hepatol. 2019;13(5):447–461. doi: https://doi.org/10.1080/17474124.2019.1595589

34. Ferraioli G, Soares Monteiro LB. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019;25(40):6053–6062. doi: https://doi.org/10.3748/wjg.v25.i40.6053

35. Ferraioli G, Calcaterra V, Lissandrin R, et al. Noninvasive assessment of liver steatosis in children: the clinical value of controlled attenuation parameter. BMC Gastroenterol. 2017;17(1):61. doi: https://doi.org/10.1186/s12876-017-0617-6

36. Pu K, Wang Y, Bai S, et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC gastroenterol. 2019;19(1):51. doi: https://doi.org/10.1186/s12876-019-0961-9

37. Shin J, Kim MJ, Shin HJ, et al. Quick assessment with controlled attenuation parameter for hepatic steatosis in children based on MRI-PDFF as the gold standard. BMC Pediatr. 2019;19(1):112. doi: https://doi.org/10.1186/s12887-019-1485-8

38. Schwimmer JB, Middleton MS, Behling C, et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology. 2015;69(6):1887–1895. https://doi.org/10.1002/hep.27666

39. Verhaegh P, Bavalia R, Winkens B, et al. Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):837–861. doi: https://doi.org/10.1016/j.cgh.2017.08.024

40. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321. doi: https://doi.org/10.1002/hep.20701

41. Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease. Gastroenterology. 2016;150(8):1798–1810. doi: https://doi.org/10.1053/j.gastro.2016.03.009

42. Papatheodoridi M, Hiriart JB, Lupsor-Platon M, et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol. 2021;74(5):1109–1116. doi: https://doi.org/10.1016/j.jhep.2020.11.050

43. Petroff D, Blank V, Newsome PN, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(3):185–198. doi: https://doi.org/10.1016/S2468-1253(20)30357-5

44. Chen BR, Pan CQ. Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 2022;46(1):101755. doi: https://doi.org/10.1016/j.clinre.2021.101755

45. Nobili V, Alisi A, Vania A, et al. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med. 2009;7:21. doi: https://doi.org/10.1186/17417015-7-21

46. Yang HR, Kim HR, Kim MJ, et al. Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. World J Gastroenterol. 2012;18(13):1525–1530. doi: https://doi.org/10.3748/wjg.v18.i13.1525

47. Lin YC, Wu CC, Ni YH. New perspectives on genetic prediction for pediatric metabolic associated fatty liver disease. Front Pediatr. 2020;8:603654. doi: https://doi.org/10.3389/fped.2020.603654

48. González-Ruiz K, Ramírez-Vélez R, Correa-Bautista JE, et al. The Effects of Exercise on Abdominal Fat and Liver Enzymes in Pediatric Obesity: A Systematic Review and Meta-Analysis. Child Obes. 2017;13(4):272–282. doi: https://doi.org/10.1089/chi.2017.0027

49. Keating SE, Hackett DA, George J, Johnson NA. Exercise and nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57(1):157–166. doi: https://doi.org/10.1016/j.jhep.2012.02.023

50. Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol. 2017;66(1):142–152. doi: https://doi.org/10.1016/j.jhep.2016.08.023

51. WHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization; 2020.

52. Ramon-Krauel M, Salsberg SL, Ebbeling CB, et al. A lowglycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes. 2013;9(3):252–260. doi: https://doi.org/10.1089/chi.2013.0022

53. Nobili V, Marcellini M, Devito R, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006;44(2):458–465. doi: https://doi.org/10.1002/hep.21262

54. de Ruyter JC, Olthof MR, Seidell JC, Katan M. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med. 2012;367(15):1397–1406. doi: https://doi.org/10.1056/NEJMoa1203034

55. Ebbeling CB, Feldman HA, Chomitz VR, et al. A randomized trial of sugar-sweetened beverages and adolescent body weight. N Engl J Med. 2012;367(15):1407–1416. doi: https://doi.org/10.1056/NEJMoa1203388

56. Schwimmer JB, Ugalde-Nicalo P, Welsh JA, et al. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial. JAMA. 2019;321(3):256– 265. doi: https://doi.org/10.1001/jama.2018.20579

57. Lee D, Chiavaroli L, Ayoub-Charette S, et al. Important food sources of fructose-containing sugars and non-alcoholic fatty liver disease: A systematic review and meta-analysis of controlled trials. Nutrients. 2022;14(14):2846. doi: https://doi.org/10.3390/nu14142846

58. Cohen CC, Li KW, Alazraki AL, et al. Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease. J Clin Invest. 2021;131(24):e150996. doi: https://doi.org/10.1172/JCI150996

59. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829– 846. doi: https://doi.org/10.1016/j.jhep.2017.05.016

60. Pacifico L, Bonci E, Di Martino M, et al. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2015;25(8):734–741. doi: https://doi.org/10.1016/j.numecd.2015.04.003

61. Janczyk W, Lebensztejn D, Wierzbicka-Rucińska A, et al. Omega-3 fatty acids therapy in children with nonalcoholic fatty liver disease: a randomized controlled trial. J Pediatr. 2015;166(6):1358–1363. doi: https://doi.org/10.1016/j.jpeds.2015.01.056

62. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659–1668. doi: https://doi.org/10.1001/jama.2011.520

63. Flisiak-Jackiewicz M, Lebensztejn DM. Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children. Clin Exp Hepatol. 2019;5(1):11–21. doi: https://doi.org/10.5114/ceh.2019.83152

64. Cheng FS, Pan D, Chang B, et al. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. World J Clin Cases. 2020;8(8):1361–1384. doi: https://doi.org/10.12998/wjcc.v8.i8.1361

65. Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39(11):1276–1285. doi: https://doi.org/10.1111/apt.12758

66. Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011;52(6):740–743. doi: https://doi.org/10.1097/MPG.0b013e31821f9b85

67. Famouri F, Shariat Z, Hashemipour M, et al. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J Pediatr Gastroenterol Nutr. 2017;64(3):413–417. doi: https://doi.org/10.1097/MPG.0000000000001422

68. Temple JL, Cordero P, Li J, et al. A Guide to nonalcoholic fatty liver disease in childhood and adolescence. Int J Mol Sci. 2016;17(6):947. doi: https://doi.org/10.3390/ijms17060947

69. Lin X, Mai M, He T, et al. Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2022;16(6):537–545. doi: https://doi.org/10.1080/17474124.2022.2083605

70. Bjelakovic GI, Nikolova D, Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm? PLoS One. 2013;8(9):e74558. doi: https://doi.org/10.1371/journal.pone.0074558

71. Bjelakovic G, Nikolova D, Gluud LL, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2012;2012(3):CD007176. doi: https://doi.org/10.1002/14651858.CD007176.pub2

72. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–690. doi: https://doi.org/10.1016/S0140-6736(15)00803-X

73. Ozhirenie u detei: Clinical guidelines. Russian Association of Endocrinologists; Society of Bariatric Surgeons. Moscow: Ministry of Health of Russia; 2024. 79 p. (In Russ). Доступно по: https://cr.minzdrav.gov.ru/preview-cr/229_3. Ссылка активна на 03.04.2025.

74. Vos MB, Jin R, Konomi JV, et al. A randomized, controlled, crossover pilot study of losartan for pediatric nonalcoholic fatty liver disease. Pilot Feasibility Stud. 2018;4:109. doi: https://doi.org/10.1186/s40814-018-0306-4

75. Inge TH, Courcoulas AP, Jenkins TM, et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med. 2016;374(2):113–123. doi: https://doi.org/10.1056/NEJMoa1506699

76. Alqahtani AR, Elahmedi MO, Al Qahtani A. Co-morbidity resolution in morbidly obese children and adolescents undergoing sleeve gastrectomy. Surg Obes Relat Dis. 2014;10(5):842–850. doi: https://doi.org/10.1016/j.soard.2014.01.020

77. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–654.e1–e9; quiz e39– e40. doi: https://doi.org/10.1016/j.cgh.2014.04.014

78. Bedossa P. Current histological classification of NAFLD: strength and limitations. Hepatol Int. 2013;7(Suppl 2):765–770. doi: https://doi.org/10.1007/s12072-013-9446-z

79. Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60(2):565–575. doi: https://doi.org/10.1002/hep.27173